CalciMedica (NASDAQ:CALC) Trading Up 1% – Should You Buy?

CalciMedica, Inc. (NASDAQ:CALC)’s share price rose 1% during mid-day trading on Monday . The company traded as high as $4.15 and last traded at $4.12. Approximately 4,224 shares traded hands during trading, a decline of 86% from the average daily volume of 31,052 shares. The stock had previously closed at $4.08.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on CALC shares. Singular Research upgraded shares of CalciMedica to a “moderate buy” rating in a research report on Friday, June 28th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of CalciMedica in a report on Tuesday, August 13th. Finally, Oppenheimer upped their price objective on CalciMedica from $14.00 to $20.00 and gave the stock an “outperform” rating in a report on Wednesday, July 10th.

CalciMedica Stock Up 1.0 %

The business’s fifty day moving average is $4.30 and its 200 day moving average is $4.66. The stock has a market cap of $44.29 million, a PE ratio of -1.92 and a beta of 1.27.

CalciMedica (NASDAQ:CALC) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.03. As a group, analysts predict that CalciMedica, Inc. will post -2.21 EPS for the current year.

Insider Buying and Selling at CalciMedica

In other news, Director Robert N. Wilson purchased 54,000 shares of the business’s stock in a transaction dated Friday, August 23rd. The stock was acquired at an average price of $3.72 per share, with a total value of $200,880.00. Following the purchase, the director now directly owns 364,196 shares of the company’s stock, valued at $1,354,809.12. This represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Over the last 90 days, insiders have bought 65,000 shares of company stock valued at $243,120. Insiders own 53.30% of the company’s stock.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.